Allergy Immunotherapy Advances: HDM Market Analysis - Pagina 12 di 112

Lower-Limb Spasticity Market: In-Depth Epidemiology Insights and Forecast Through 2034

DelveInsight’s “Lower-Limb Spasticity Market Insights, Epidemiology, and Market Forecast-2034” report provides a thorough understanding of Lower-Limb Spasticity, historical and projected epidemiology along with the Lower-Limb Spasticity market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Essential Highlights from the Lower-Limb Spasticity Market Report

The expansion in Lower-Limb Spasticity Market Size is a direct result of the growing patient population and expected introduction of emerging therapies in the 7MM.
According to DelveInsight analysis, the Lower-Limb Spasticity Market is projected to experience growth at a notable CAGR.
The prominent Lower-Limb Spasticity Companies include Ipsen, Allergan, Merz Pharmaceuticals GmbH, Allergan, GlaxoSmithKline, among others.
Investigational Lower-Limb Spasticity Pipeline Therapies include Botox®, Xeomin, IncobotulinumtoxinA, NT 201, GSK1358820, among others.

Maintain a competitive edge in the Lower-Limb Spasticity Therapeutics Market with DelveInsight’s Strategic Report @ Lower-Limb Spasticity Market Outlook

Lower-Limb Spasticity Epidemiology Classification in the 7MM

The epidemiology segment of Lower-Limb Spasticity delivers insights into both historical and present patient populations, along with forecasted trends across seven major countries. This segment facilitates understanding the factors driving present and projected trends through evaluation of various studies and perspectives from key opinion leaders. Moreover, this component of the market report furnishes information on the diagnosed patient pool, trends, and underlying assumptions.

Access the report to understand which factors are influencing Lower-Limb Spasticity Epidemiology trends @ Lower-Limb Spasticity Prevalence

Lower-Limb Spasticity Drugs Market

The Lower-Limb Spasticity Drugs Market is projected to experience considerable growth in upcoming years as additional targeted therapies obtain regulatory approval and enter clinical practice. Furthermore, continuous research initiatives focused on enhanced understanding of the molecular mechanisms underlying Lower-Limb Spasticity signaling in Lower-Limb Spasticity are expected to identify new therapeutic targets and further broaden treatment options for patients.

Lower-Limb Spasticity Treatment Market Landscape

The Lower-Limb Spasticity treatment market landscape has experienced notable advancements over recent years, with targeted therapies serving a critical role in enhancing outcomes for patients. Among these targeted therapies, the emergence of Lower-Limb Spasticity has attracted attention in the medical community, presenting both challenges and opportunities in treatment strategies.

To discover more about Lower-Limb Spasticity treatment guidelines, visit @ Lower-Limb Spasticity Treatment Market Landscape

Lower-Limb Spasticity Market Outlook

The report’s perspective on the Lower-Limb Spasticity market facilitates developing a thorough understanding of historical, current, and projected trends. This is accomplished by examining the influence of existing Lower-Limb Spasticity therapies, unmet needs, along with drivers, barriers, and the demand for innovative technology. This segment delivers detailed insights into the trends of each marketed Lower-Limb Spasticity drug and late-stage pipeline therapy.

Lower-Limb Spasticity Drugs Uptake

The drug chapter of the Lower-Limb Spasticity report offers a thorough analysis of both marketed drugs and late-stage pipeline drugs for this condition. It examines the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages and disadvantages of each drug, along with the latest news and press releases related to Lower-Limb Spasticity.

Leading Lower-Limb Spasticity Companies

Ipsen, Allergan, Merz Pharmaceuticals GmbH, Allergan, GlaxoSmithKline, among others.

Discover more about the FDA-approved drugs for Lower-Limb Spasticity @ Drugs for Lower-Limb Spasticity Treatment

Parameters of the Lower-Limb Spasticity Market Report

Coverage- 7MM
Study Period- 2020-2034
Lower-Limb Spasticity Companies- Ipsen, Allergan, Merz Pharmaceuticals GmbH, Allergan, GlaxoSmithKline, among others.
Lower-Limb Spasticity Pipeline Therapies- Botox®, Xeomin, IncobotulinumtoxinA, NT 201, GSK1358820, among others.
Lower-Limb Spasticity Market Dynamics: Lower-Limb Spasticity Market Drivers and Barriers
Lower-Limb Spasticity Market Access and Reimbursement, Unmet Needs and Future Perspectives

Explore more about Lower-Limb Spasticity Drugs in development @ Lower-Limb Spasticity Clinical Trials Assessment

Table of Content

Key Insights
Lower-Limb Spasticity Executive Summary
Competitive Intelligence Analysis for Lower-Limb Spasticity
Lower-Limb Spasticity: Market Overview at a Glance
Lower-Limb Spasticity: Disease Background and Overview
Patient Journey
Lower-Limb Spasticity Epidemiology and Patient Population
Treatment Algorithm, Current Treatment, and Medical Practices
Lower-Limb Spasticity Unmet Needs
Key Endpoints of Lower-Limb Spasticity Treatment
Lower-Limb Spasticity Marketed Products
Lower-Limb Spasticity Emerging Therapies
Lower-Limb Spasticity: Seven Major Market Analysis
Attribute analysis
7MM: Lower-Limb Spasticity Market Outlook
Access and Reimbursement Overview of Lower-Limb Spasticity
KOL Views
Lower-Limb Spasticity Market Drivers
Lower-Limb Spasticity Market Barriers
Appendix
DelveInsight Capabilities
Disclaimer
About DelveInsight

About Us

DelveInsight is a prominent healthcare-focused market research and consulting organization that delivers clients with superior market intelligence and analysis to facilitate informed business decisions. With a team of seasoned industry experts and a comprehensive understanding of the life sciences and healthcare sectors, we provide customized research solutions and insights to clients worldwide. Connect with us to obtain high-quality, accurate, and real-time intelligence to remain ahead of the growth curve.

Contact Information

Kanishk

kkumar@delveinsight.com

Chronic and Acute Pain Market: Comprehensive Epidemiology Analysis and Forecast Through 2034

DelveInsight’s “Chronic and Acute Pain Market Insights, Epidemiology, and Market Forecast-2034” report provides a thorough understanding of Chronic and Acute Pain, historical and projected epidemiology along with the Chronic and Acute Pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Explore which therapies are projected to capture the Chronic and Acute Pain Market Share @ Chronic and Acute Pain Market Outlook

Essential Highlights from the Chronic and Acute Pain Market Report

The expansion in Chronic and Acute Pain Market Size is a direct result of the growing patient population and expected introduction of emerging therapies in the 7MM.
According to DelveInsight analysis, the Chronic and Acute Pain Market is projected to experience growth at a notable CAGR.
The prominent Chronic and Acute Pain Companies include Endo Pharmaceuticals, ElectroCore Inc., Tonix Pharmaceuticals Inc., Zosano Pharma Corporation, INSYS Therapeutics Inc., among others.
Investigational Chronic and Acute Pain Pipeline Therapies include Fentanyl sublingual spray, C213 Microneedle System, TNX-102 SL, Lidoderm® among others.

Maintain a competitive edge in the Chronic and Acute Pain Therapeutics Market with DelveInsight’s Strategic Report @ Chronic and Acute Pain Market Outlook

Chronic and Acute Pain Epidemiology Classification in the 7MM

The epidemiology segment of Chronic and Acute Pain delivers insights into both historical and present patient populations, along with forecasted trends across seven major countries. This segment facilitates understanding the factors driving present and projected trends through evaluation of various studies and perspectives from key opinion leaders. Moreover, this component of the market report furnishes information on the diagnosed patient pool, trends, and underlying assumptions.

Access the report to understand which factors are influencing Chronic and Acute Pain Epidemiology Trends @ Chronic and Acute Pain Prevalence

Chronic and Acute Pain Drugs Market

The Chronic and Acute Pain Drugs Market is projected to experience considerable growth in upcoming years as additional targeted therapies obtain regulatory approval and enter clinical practice. Furthermore, continuous research initiatives focused on enhanced understanding of the molecular mechanisms underlying Chronic and Acute Pain signaling in Chronic and Acute Pain are expected to identify new therapeutic targets and further broaden treatment options for patients.

Chronic and Acute Pain Treatment Market Landscape

The Chronic and Acute Pain treatment market landscape has experienced notable advancements over recent years, with targeted therapies serving a critical role in enhancing outcomes for patients. Among these targeted therapies, the emergence of Chronic and Acute Pain has attracted attention in the medical community, presenting both challenges and opportunities in treatment strategies.

To discover more about Chronic and Acute Pain treatment guidelines, visit @ Chronic and Acute Pain Treatment Market Landscape

Chronic and Acute Pain Market Outlook

The report’s perspective on the Chronic and Acute Pain market facilitates developing a thorough understanding of historical, current, and projected trends. This is accomplished by examining the influence of existing Chronic and Acute Pain therapies, unmet needs, along with drivers, barriers, and the demand for innovative technology. This segment delivers detailed insights into the trends of each marketed Chronic and Acute Pain drug and late-stage pipeline therapy.

Chronic and Acute Pain Drugs Uptake

The drug chapter of the Chronic and Acute Pain report offers a thorough analysis of both marketed drugs and late-stage pipeline drugs for this condition. It examines the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages and disadvantages of each drug, along with the latest news and press releases related to Chronic and Acute Pain.

Leading Chronic and Acute Pain Companies

Endo Pharmaceuticals, ElectroCore Inc., Tonix Pharmaceuticals Inc., Zosano Pharma Corporation, INSYS Therapeutics Inc., among others.

Discover more about the FDA-approved drugs for Chronic and Acute Pain @ Drugs for Chronic and Acute Pain Treatment

Parameters of the Chronic and Acute Pain Market Report

Coverage- 7MM
Study Period- 2020-2034
Chronic and Acute Pain Companies- Endo Pharmaceuticals, ElectroCore Inc., Tonix Pharmaceuticals Inc., Zosano Pharma Corporation, INSYS Therapeutics Inc., among others.
Chronic and Acute Pain Pipeline Therapies- Fentanyl sublingual spray, C213 Microneedle System, TNX-102 SL, Lidoderm® among others.
Chronic and Acute Pain Market Dynamics: Chronic and Acute Pain Market Drivers and Barriers
Chronic and Acute Pain Market Access and Reimbursement, Unmet Needs and Future Perspectives

Explore more about Chronic and Acute Pain Drugs in development @ Chronic and Acute Pain Clinical Trials Assessment

Key Insights
Chronic and Acute Pain Executive Summary
Competitive Intelligence Analysis for Chronic and Acute Pain
Chronic and Acute Pain: Market Overview at a Glance
Chronic and Acute Pain: Disease Background and Overview
Patient Journey
Chronic and Acute Pain Epidemiology and Patient Population
Treatment Algorithm, Current Treatment, and Medical Practices
Chronic and Acute Pain Unmet Needs
Key Endpoints of Chronic and Acute Pain Treatment
Chronic and Acute Pain Marketed Products
Chronic and Acute Pain Emerging Therapies
Chronic and Acute Pain: Seven Major Market Analysis
Attribute analysis
7MM: Chronic and Acute Pain Market Outlook
Access and Reimbursement Overview of Chronic and Acute Pain
KOL Views
Chronic and Acute Pain Market Drivers
Chronic and Acute Pain Market Barriers
Appendix
DelveInsight Capabilities
Disclaimer
About DelveInsight

About Us

Contact Information

Kanishk

kkumar@delveinsight.com

JAK Inhibitors Market Insights, Epidemiology, and Market Forecast 2034

DelveInsight’s “JAK Inhibitors Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of the JAK Inhibitors, historical and forecasted epidemiology as well as the JAK Inhibitors market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover which therapies are expected to grab the JAK Inhibitors Market Share @ JAK Inhibitors Market Outlook

Key Takeaways from the JAK Inhibitors Market Research Report

In March 2025, Incyte announced positive topline results from two Phase 3 clinical trials of povorcitinib in patients with hidradenitis suppurativa. The trials demonstrated that a significantly higher proportion of patients treated with povorcitinib once daily (QD) achieved Hidradenitis Suppurativa Clinical Response (HiSCR)—defined as a ≥50% reduction from baseline in total abscess and inflammatory nodule (AN) count, with no increase in abscess or draining tunnel count—compared to those receiving placebo.
In January 2025, VGT-1849A, a novel antisense oligonucleotide-based Janus kinase 2 (JAK2) inhibitor, received Orphan Drug Designation from the FDA for the treatment of polycythemia vera (PV), recognizing its potential to address an unmet need in this rare hematologic disorder.
In April 2025, NS Pharma, Inc. announced that the U.S. FDA granted Orphan Drug Designation to NS-229 for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA). NS-229 is being developed as a selective Janus kinase 1 (JAK1) inhibitor aimed at regulating immune cell function and preventing immune-mediated tissue damage.
In July 2024, Sun Pharmaceutical Industries Limited announced that the U.S. FDA approved LEQSELVI™ (deuruxolitinib) 8 mg tablets for the treatment of adults with severe alopecia areata, marking a significant advancement in addressing the unmet needs of patients suffering from this autoimmune hair loss disorder.
JAKAFI (ruxolitinib), the first FDA-approved JAK inhibitor, continues to lead the market with robust performance, generating USD 773 million in Q4 2024 revenue (+11% YoY) and USD 2.8 billion for the full year (+8% YoY), underscoring its blockbuster status and the growing demand for JAK-targeted therapies.
RINVOQ (upadacitinib) achieved impressive global net revenues of USD 5.97 billion, a nearly 50% year-over-year increase, highlighting its growing clinical adoption. Of this, USD 4.26 billion was generated from the U.S. market, reflecting its strong domestic performance and therapeutic impact.
The leading JAK Inhibitors Companies such as Incyte Corporation, AbbVie, Sanofi, Pfizer, Eli Lilly, Bristol Myers Squibb, Celon Pharma, Aclaris Therapeutics, AstraZeneca, Ajax Therapeutics, and others.
Promising JAK Inhibitors Pipeline Therapies such as Povorcitinib, CPL409116, AJ1-11095, and others.

Discover which therapies are expected to grab the JAK Inhibitors market share @ JAK Inhibitors Market Research

JAK Inhibitors Epidemiology Segmentation in the 7MM

JAK Inhibitors Target Patient Population
Disease-specific Patient Pool (Rheumatoid Arthritis, Myelofibrosis, Ulcerative Colitis, Atopic Dermatitis, Psoriatic Arthritis, Polycythemia Vera, Graft-Versus-Host Disease, Hidradenitis Suppurativa, Alopecia Areata)
Severity-based Patient Segmentation
Treatment-eligible Patient Population

Download the report to understand which factors are driving JAK Inhibitors epidemiology trends @ JAK Inhibitors Prevalence

JAK Inhibitors Emerging Drugs

Povorcitinib (INCB054707): Incyte Corporation

Povorcitinib (INCB054707) is an oral small-molecule JAK1 inhibitor. The chemical structure for povorcitinib was revealed in WHO proposed INN list 126 (Jan 2022), in which it was described as a Janus kinase inhibitor and anti-inflammatory agent. The drug is also being evaluated in Phase II Prurigo Nodularis clinical trials, and others. Currently, the drug is in Phase III stage of Hidradenitis suppurativa clinical trial. In March 2025, Incyte announced positive topline results from two Phase 3 clinical trials of povorcitinib in hidradenitis suppurativa patients.

CPL409116: Celon Pharma

CPL 409116 is the first in class dual JAK/ROCK inhibitor in clinical development and is designed to generate anti-inflammatory and anti-fibrotic effects in selected autoimmune diseases. CPL’116 was administered orally in single ascending doses in healthy volunteers in order to assess safety and pharmacokinetic parameters (PK). No adverse events associated with administration of the investigational drug were observed, and the trial met its primary endpoint. Currently the drug is in Phase II stage of development for autoimmune indications including in rheumatoid arthritis patients with coexisting interstitial lung disease.

AJ1-11095: Ajax Therapeutics

AJ1-11095 is a first-in-class type II JAK2 inhibitor being developed for the treatment of myelofibrosis. In November 2024, Ajax Therapeutics announced that the first patient had been enrolled in a Phase 1 clinical trial (NCT06343805) evaluating this novel therapy. In May 2024, Ajax Therapeutics raised USD 95 million in a Series C funding round and announced that the FDA had cleared the company to begin its first clinical trial.

JAK Inhibitors Drugs Market Insights

The JAK Inhibitors market is experiencing substantial growth driven by expanding therapeutic applications, technological advancements, and strong commercial performance. JAK enzymes play a critical role in cytokine signaling and immune system regulation, making them a prime target for treating autoimmune and hematologic disorders. The shift toward increased selectivity and disease-specific targeting distinguishes the evolving treatment landscape, with newer drugs aiming for selective JAK1 or TYK2 inhibition to reduce side effects like infections or thrombosis.

JAK Inhibitors Market Outlook

The Janus Kinase (JAK) inhibitors market is witnessing rapid expansion, driven by increasing therapeutic applications, technological advancements, and strong commercial performance. Several JAK inhibitors are currently approved and available, targeting a range of autoimmune and hematologic conditions. JAKAFI (ruxolitinib) by Incyte was the first FDA-approved JAK inhibitor. XELJANZ (tofacitinib) by Pfizer, RINVOQ (upadacitinib) by AbbVie, OLUMIANT (baricitinib) by Eli Lilly, SOTYKTU (deucravacitinib) by Bristol Myers Squibb, and others are also approved.

The market is led by blockbuster drugs such as JAKAFI (ruxolitinib), which generated USD 2.8 billion in 2024, and RINVOQ (upadacitinib), with revenues reaching nearly USD 6 billion, highlighting widespread clinical adoption. Beyond traditional indications like rheumatoid arthritis and myelofibrosis, JAK inhibitors are now being explored for diseases such as systemic lupus erythematosus (SLE), immune thrombocytopenia (ITP), and light chain amyloidosis.

To learn more about JAK Inhibitors treatment guidelines, visit @ JAK Inhibitors Treatment Market Landscape

JAK Inhibitors Companies

Incyte Corporation, AbbVie, Sanofi, Pfizer, Eli Lilly, Bristol Myers Squibb, Celon Pharma, Aclaris Therapeutics, AstraZeneca, Ajax Therapeutics, and others.

JAK Inhibitors Treatment Landscape

The current treatment landscape for JAK inhibitors reflects significant clinical and commercial growth, driven by their expanding role in managing chronic immune-mediated and hematologic disorders. Initially introduced for conditions like myelofibrosis and rheumatoid arthritis, JAK inhibitors have rapidly progressed into mainstream therapy for a wide array of indications, including ulcerative colitis, atopic dermatitis, psoriatic arthritis, and alopecia areata. Their ability to modulate multiple cytokine pathways by inhibiting JAK-STAT signaling makes them versatile and effective across disease areas characterized by immune dysregulation.

What distinguishes the evolving treatment landscape is the shift toward increased selectivity and disease-specific targeting. While earlier agents like XELJANZ (tofacitinib) and JAKAFI (ruxolitinib) showed broad JAK inhibition, newer drugs such as RINVOQ (upadacitinib), SOTYKTU (deucravacitinib), and povorcitinib aim for selective JAK1 or TYK2 inhibition, reducing side effects like infections or thrombosis.

Learn more about the FDA-approved drugs for JAK Inhibitors Treatment @ Drugs for JAK Inhibitors Treatment

Scope of the JAK Inhibitors Market Report

Coverage – 7MM
Study Period – 2020-2034
JAK Inhibitors Companies – Incyte Corporation, AbbVie, Sanofi, Pfizer, Eli Lilly, Bristol Myers Squibb, Celon Pharma, Aclaris Therapeutics, AstraZeneca, Ajax Therapeutics, and others
JAK Inhibitors Pipeline Therapies – Povorcitinib, CPL409116, AJ1-11095, VGT-1849A, NS-229, and others
JAK Inhibitors Market Dynamics: JAK Inhibitors Market Drivers and Barriers

Discover more about JAK Inhibitors Drugs in development @ JAK Inhibitors Ongoing Clinical Trials Analysis

Table of Content

Key Insights
Report Introduction
Executive Summary of Janus Kinase (JAK) Inhibitor
Key Events
Janus Kinase (JAK) Inhibitor Market Overview At A Glance
Background And Overview
JAK Inhibitor Target Population
Janus Kinase (JAK) Inhibitor Marketed Drugs
JAK Inhibitor Emerging Drugs
Janus Kinase (JAK) Inhibitor: The 7MM Analysis
JAK Inhibitor Unmet Needs
SWOT Analysis
KOL Views
Market Access and Reimbursement
Appendix
DelveInsight Capabilities
Disclaimer
About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Information

Kanishk

kkumar@delveinsight.com

Physiotherapy Equipment Market Insights, Competitive Landscape, and Market Forecast 2034

DelveInsight’s “Physiotherapy Equipment Market Insights, Competitive Landscape, and Market Forecast-2034” report delivers an in-depth understanding of the Physiotherapy Equipment, historical and forecasted market trends as well as the Physiotherapy Equipment market dynamics globally, which comprises North America, Europe, Asia-Pacific, and Rest of the World.

Recent Developments of Physiotherapy Equipment Clinical Trials

In June 2025, Bioness Medical acquired the assets and operations of Harmonic Bionics for an undisclosed sum. The deal is intended to strengthen Bioness Medical’s range of upper-limb robotic rehabilitation products and speed up the market rollout of Harmonic Bionics’ soft robotic, sensor-based therapy technologies.
In January 2025, Kaphaphysio took part in Arab Health 2025 held at the Dubai World Trade Centre. During the event, the company presented a range of advanced physiotherapy machines aimed at improving patient care and recovery, including a standard line for wholesalers, a class line, and a premium line designed for select distributors.

Stay ahead in the Physiotherapy Equipment Market with DelveInsight’s Strategic Report @ Physiotherapy Equipment Market Report

Key Takeaways from the Physiotherapy Equipment Market Report

The increase in Physiotherapy Equipment Market Size is a direct consequence of the rising prevalence of chronic diseases and musculoskeletal disorders, growing geriatric population, and increasing sports and work-related injuries globally.
As per DelveInsight analysis, the Physiotherapy Equipment Market is anticipated to witness growth at a considerable CAGR of 7.57% during the forecast period from 2026 to 2034.
The Global Physiotherapy Equipment Market is expected to increase from USD 21,718.96 million in 2025 to USD 38,835.63 million by 2034.
The leading Physiotherapy Equipment Companies such as BTL Industries, Dynatronics Corporation, Enovis Corporation, EMS Physio Ltd., Enraf-Nonius B.V., Zimmer MedizinSysteme GmbH, Performance Health, Storz Medical AG, Life Care Systems, Zynex, Inc., Biodex Medical Systems, Inc., Invacare Corporation, HMS Medical Systems, Medline Industries, LP, and others.
In the product type segment, the electrotherapy category is estimated to account for the largest market share of 35% in 2025.
North America is expected to dominate the Physiotherapy Equipment Market with 40% market share in 2025.

Physiotherapy Equipment Market Segmentation

The market segmentation section of Physiotherapy Equipment offers insights into market distribution across different categories. This comprehensive analysis covers segmentation by Product Type (Electrotherapy, Ultrasound Therapy, Shockwave Therapy, Laser Therapy, and Others), Application (Musculoskeletal Disorders, Neurology Disorders, Cardiovascular Disorders, and Others), End-Users (Hospitals, Physiotherapy Centers, Rehabilitation Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World). This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders.

Download the report to understand which factors are driving Physiotherapy Equipment Market trends @ Physiotherapy Equipment Market Analysis

Physiotherapy Equipment Market

The Physiotherapy Equipment Market is expected to witness substantial growth in the coming years as more advanced technologies receive regulatory approval and enter clinical practice. The market is expanding rapidly due to the rising prevalence of chronic diseases and musculoskeletal disorders, a growing geriatric population, and an increasing number of sports and work-related injuries. Additionally, ongoing research efforts and technological advancements, including AI-integrated systems, robotic-assisted therapy devices, and wearable rehabilitation equipment, are likely to uncover new therapeutic applications and further expand treatment options for patients.

Physiotherapy Equipment Market Landscape

The Physiotherapy Equipment market landscape has witnessed significant advancements over the past years, with innovative technologies playing a crucial role in improving outcomes for patients. The surge in chronic pain and mobility issues is driving demand for non-invasive rehabilitation solutions, while the aging population requires ongoing therapy for age-related conditions. The integration of advanced bioinformatics tools and artificial intelligence is enhancing treatment precision, and the rise in injuries among athletes and workers is boosting the need for advanced physiotherapy devices that support faster recovery and functional restoration, presenting both challenges and opportunities in treatment strategies.

To learn more about Physiotherapy Equipment applications, visit @ Physiotherapy Equipment Market Landscape

Physiotherapy Equipment Market Outlook

The report’s outlook on the Physiotherapy Equipment market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing technologies, unmet needs, as well as drivers, barriers, and the demand for advanced innovations. This section provides detailed insights into the trends of each product category and technology platform. The market is characterized by moderately concentrated competition, with established global manufacturers and emerging innovators focusing on specialized rehabilitation technologies.

Physiotherapy Equipment Market Dynamics

The market dynamics section provides a comprehensive analysis of both market drivers and barriers. Key drivers include the rising incidence of chronic diseases and musculoskeletal disorders, growing geriatric population, increasing sports and work-related injuries, advancements in next-generation technologies, integration of AI and bioinformatics, and growing preference for non-invasive treatment options. However, the market faces notable challenges including shortage of skilled professionals and high cost of advanced equipment, which together constrain broader adoption and accessibility.

Major Physiotherapy Equipment Companies

BTL Industries, Dynatronics Corporation, Enovis Corporation, EMS Physio Ltd., Enraf-Nonius B.V., Zimmer MedizinSysteme GmbH, Performance Health, Storz Medical AG, Life Care Systems, Zynex, Inc., Biodex Medical Systems, Inc., Invacare Corporation, HMS Medical Systems, Medline Industries, LP, and others.

Learn more about Physiotherapy Equipment technologies @ Physiotherapy Equipment Companies

Scope of the Physiotherapy Equipment Market Report

Coverage- Global
Study Period- 2023-2034
Physiotherapy Equipment Companies- BTL Industries, Dynatronics Corporation, Enovis Corporation, EMS Physio Ltd., Enraf-Nonius B.V., Zimmer MedizinSysteme GmbH, Performance Health, Storz Medical AG, Life Care Systems, Zynex, Inc., Biodex Medical Systems, Inc., Invacare Corporation, HMS Medical Systems, Medline Industries, LP, and others.
Physiotherapy Equipment Market Segmentation- Product Type, Application, End-Users, and Geography
Physiotherapy Equipment Market Dynamics: Market Drivers and Barriers
Physiotherapy Equipment Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Physiotherapy Equipment Market developments @ Physiotherapy Equipment Market Assessment

Table of Content

Physiotherapy Equipment Market Report Introduction
Physiotherapy Equipment Market Executive Summary
Physiotherapy Equipment Market Key Factors Analysis
Impact Analysis
Regulatory Analysis
Physiotherapy Equipment Market Porter’s Five Forces Analysis
Physiotherapy Equipment Market Assessment
Competitive Landscape
Startup Funding & Investment Trends
Physiotherapy Equipment Market Company and Product Profiles
KOL Views
Project Approach
About DelveInsight
Disclaimer & Contact Us

About Us

Contact Information

Kanishk

kkumar@delveinsight.com

DNA Microarray Market: Strong Growth Forecast Through 2034 DelveInsight

DelveInsight’s “DNA Microarray Market Insights, Epidemiology, and Market Forecast-2034” report offers an in-depth understanding of the DNA Microarray market, historical and forecasted trends as well as the DNA Microarray market dynamics in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the DNA Microarray market outlook, drug uptake, treatment scenario and trends, Click here; DNA Microarray Market Forecast

Some of the key facts of the DNA Microarray Market Report:

In May 2025, Agilent Technologies received European regulatory approval for its SurePrint G3 Human CNV Microarray, expanding its clinical and research applications across European markets.
In May 2025, Illumina secured approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for its TruSight Oncology Comprehensive test, supporting more efficient pan-tumor profiling in clinical practice.
In April 2025, Eurofins Genomics expanded its service capabilities by acquiring the Sanger sequencing business of LGC Group.
The DNA Microarray market size was valued at approximately USD 2,596.21 million in 2025 and is anticipated to reach USD 4,797.63 million by 2034, growing at a CAGR of 7.11% during the study period (2026-2034).
In 2025, North America accounted for the largest DNA Microarray market share at approximately 41.39%, driven by strong presence of leading biotechnology companies and advanced healthcare infrastructure.
In the Microarray type segment, oligonucleotide DNA Microarrays dominated with approximately 61.32% market share in 2025, due to their high specificity, reproducibility, and scalability in genomic analysis.
In the application segment, gene expression analysis is projected to dominate with around 53.42% of the market share in 2025, owing to its critical role in understanding disease mechanisms and enabling precision medicine.
According to the World Health Organization (2026) and the International Agency for Research on Cancer (IARC), new cancer cases were projected to reach 21,325,245 in 2025, increasing to 35,281,056 by 2050, significantly driving demand for DNA Microarrays.
The anticipated launch of advanced DNA Microarray platforms with improved sensitivity, faster processing times, and enhanced data analysis capabilities is expected to drive growth in the total DNA Microarray market in the coming years.
Key DNA Microarray Companies: Thermo Fisher Scientific, Agilent Technologies, Illumina, Bio-Rad Laboratories, PerkinElmer, Merck KGaA, F. Hoffmann-La Roche Ltd., Arrayit Corporation, Phalanx Biotech Group, CapitalBio Corporation, Applied Microarrays, LC Sciences, Oxford Gene Technology, Akonni Biosystems, Arraystar Inc., Febit Holding GmbH, CustomArray Inc., Microarrays Inc., Molecular Devices, Scienion AG, and others.
Key DNA Microarray Products/Technologies: Axiom™ PangenomiX Array, Applied Biosystems™ CytoScan™ HD Accel array, SurePrint G3 Human CNV Microarray, Affymetrix GeneChip™ arrays, SurePrint G3 oligonucleotide Microarrays, Infinium™ BeadChips, and others.
The DNA Microarray market is expected to surge due to the rising prevalence of genetic and chronic diseases, increased adoption in drug discovery and development, and continuous product innovations during the forecast period.

DNA Microarray Overview

A DNA Microarray is a laboratory tool used to analyze the expression of thousands of genes simultaneously. It consists of a solid surface, such as a glass slide or chip, onto which numerous DNA probes are fixed in a grid pattern. When a labeled DNA or RNA sample is applied, complementary sequences bind to these probes, allowing researchers to measure gene activity, detect mutations, and study genetic variations in a high-throughput and efficient manner.

DNA Microarrays are widely used in gene expression profiling, mutation detection, biomarker discovery, cancer research, drug development, and personalized medicine applications.

Get a Free sample for the DNA Microarray Market Forecast, Size & Share Analysis Report

DNA Microarray Market Insights

The market insights section provides a comprehensive analysis of the DNA Microarray market trends, including technological advancements, regulatory landscape, and competitive dynamics across major markets.

DNA Microarray Market Segmentation:

The DNA Microarray market report provides detailed segmentation for the study period 2023-2034 across the following categories:

Product Type: Instruments, Consumables, Software, and Services
Microarray Type: cDNA Microarrays, Oligonucleotide DNA Microarrays, SNP (Single Nucleotide Polymorphism) Microarrays, and Comparative Genomic Hybridization (CGH) Microarrays
Application: Gene Expression Analysis, Genotyping & SNP Analysis, and Others
End-Users: Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, and Others
Geography: North America, Europe, Asia-Pacific, and Rest of the World

Download the report to understand which factors are driving DNA Microarray market trends @ DNA Microarray Market Segmentation

DNA Microarray Market Uptake and Technology Development Activities

The market uptake section focuses on the adoption rate of recently launched DNA Microarray platforms and technologies expected to enter the market during the study period. The analysis covers market uptake by technology, adoption by end-users, and revenue generation.

Moreover, the technology assessment section helps understand which platforms demonstrate the most rapid uptake and the reasons behind their widespread adoption. Additionally, it compares technologies based on market share and clinical utility.

The report also covers DNA Microarray Development Activities, providing valuable insights about different technologies in various development stages and key companies involved in advancing targeted platforms. It analyzes recent developments such as collaborations, acquisitions, mergers, licensing, patent details, and other information for emerging technologies.

DNA Microarray Technology and Key Companies

Axiom™ PangenomiX Array: Thermo Fisher Scientific
Applied Biosystems™ CytoScan™ HD Accel array: Thermo Fisher Scientific
SurePrint G3 Human CNV Microarray: Agilent Technologies
Affymetrix GeneChip™ arrays: Thermo Fisher Scientific
SurePrint G3 oligonucleotide Microarrays: Agilent Technologies
Infinium™ BeadChips: Illumina

Discover more about technologies set to grab major DNA Microarray market share @ DNA Microarray Companies

DNA Microarray Market Drivers

Rising global prevalence of cancer, cardiovascular disorders, and genetic diseases driving demand for gene expression profiling and mutation detection
Growing adoption in drug discovery and development for biomarker identification and drug response analysis
Advancements in high-throughput, cost-effective platforms with improved sensitivity and data analysis capabilities
Increasing healthcare expenditure and government funding for genomics research
Expansion of precision medicine and personalized treatment approaches
Strong presence of leading biotechnology and pharmaceutical companies investing in genomic technologies
Integration with AI and machine learning for enhanced data analysis and clinical decision support

DNA Microarray Market Barriers

High cost of instruments, consumables, and data analysis limiting adoption in smaller laboratories
Strong competition from next-generation sequencing (NGS) and other advanced genomic technologies
Stringent data privacy regulations governing clinical genomic data sharing
Limited awareness and technical expertise in developing regions
Complexity in data interpretation requiring specialized bioinformatics support
Preference shift toward more flexible and comprehensive sequencing platforms
Regulatory challenges and lengthy approval processes for clinical applications

Scope of the DNA Microarray Market Report

Study Period: 2023-2034
Coverage: 7MM
Key DNA Microarray Companies: Thermo Fisher Scientific, Agilent Technologies, Illumina, Bio-Rad Laboratories, PerkinElmer, Merck KGaA, Roche, Arrayit Corporation, Phalanx Biotech Group, CapitalBio Corporation, Applied Microarrays, LC Sciences, Oxford Gene Technology, Akonni Biosystems, Arraystar Inc., Febit Holding GmbH, CustomArray Inc., Microarrays Inc., Molecular Devices, Scienion AG, and others.
DNA Microarray Technology Assessment: Current marketed and emerging DNA Microarray platforms
DNA Microarray Market Dynamics: Market drivers and market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
DNA Microarray Unmet Needs, KOL’s views, Analyst’s views, Market Access and Reimbursement

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm exclusively focused on life sciences. We empower pharmaceutical and biotech companies with robust, end-to-end solutions for enhancing strategic decision-making and performance. Our Healthcare Consulting Services leverage market intelligence to drive growth and resolve challenges with an actionable, practical approach.

Contact Information

Kanishk

kkumar@delveinsight.com

Chronic Bronchitis Pipeline Insight, 2026

As per DelveInsight’s assessment, globally, Chronic Bronchitis pipeline constitutes numerous key companies continuously working towards developing therapies for Chronic Bronchitis treatment, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Chronic Bronchitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers and acquisition, funding, designations, and other product-related details.

“Chronic Bronchitis Pipeline Insight, 2026” report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Bronchitis Market.

Some of the key takeaways from the Chronic Bronchitis Pipeline Report:

Companies across the globe are diligently working toward developing novel Chronic Bronchitis treatment therapies with a focus on novel approaches to treat/improve the disease condition.
The therapies under development are focused on addressing challenges and seeking opportunities that could influence Chronic Bronchitis R&D.
Several potential therapies for Chronic Bronchitis are under investigation, and with the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Chronic Bronchitis market size in the coming years.

Chronic Bronchitis Overview

Chronic Bronchitis is a respiratory condition that requires effective therapeutic interventions. A better understanding of disease pathogenesis is contributing to the development of novel therapeutics for Chronic Bronchitis.

Get a Free Sample PDF Report to know more about Chronic Bronchitis Pipeline Therapeutic Assessment https://www.delveinsight.com/sample-request/chronic-bronchitis-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Chronic Bronchitis Route of Administration

Chronic Bronchitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Inhalation
Topical

Chronic Bronchitis Molecule Type

Chronic Bronchitis Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Chronic Bronchitis Pipeline Therapeutics Assessment

Chronic Bronchitis Assessment by Product Type
Chronic Bronchitis By Stage and Product Type
Chronic Bronchitis Assessment by Route of Administration
Chronic Bronchitis By Stage and Route of Administration
Chronic Bronchitis Assessment by Molecule Type
Chronic Bronchitis by Stage and Molecule Type

DelveInsight’s Chronic Bronchitis Report covers products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Chronic Bronchitis product details are provided in the report. Download the Chronic Bronchitis pipeline report to learn more about the emerging Chronic Bronchitis therapies https://www.delveinsight.com/sample-request/chronic-bronchitis-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Chronic Bronchitis Pipeline Analysis:

The Chronic Bronchitis pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Bronchitis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Bronchitis Treatment.
Chronic Bronchitis key players are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Chronic Bronchitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Bronchitis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Chronic Bronchitis drugs and therapies

https://www.delveinsight.com/sample-request/chronic-bronchitis-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Chronic Bronchitis Pipeline Market Drivers

Increase in R&D for the development of new and effective drugs for the treatment – Rising awareness of the disease, incremental healthcare spending across the world are some of the important factors that are fueling the Chronic Bronchitis Market, which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

Chronic Bronchitis Pipeline Market Barriers

However, challenges in R&D and other factors are creating obstacles in the Chronic Bronchitis Market growth.

Scope of Chronic Bronchitis Pipeline Drug Insight

Coverage: Global
Chronic Bronchitis Therapeutic Assessment: Chronic Bronchitis current marketed and Chronic Bronchitis emerging therapies
Chronic Bronchitis Market Dynamics: Chronic Bronchitis market drivers and Chronic Bronchitis market barriers

Request for Sample PDF Report for Chronic Bronchitis Pipeline Assessment and clinical trials

https://www.delveinsight.com/sample-request/chronic-bronchitis-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Report Introduction
Chronic Bronchitis
Chronic Bronchitis Current Treatment Patterns
Chronic Bronchitis – DelveInsight’s Analytical Perspective
Therapeutic Assessment
Chronic Bronchitis Late Stage Products (Phase-III)
Chronic Bronchitis Mid Stage Products (Phase-II)
Early Stage Products (Phase-I)
Pre-clinical Products and Discovery Stage Products
Inactive Products
Dormant Products
Chronic Bronchitis Discontinued Products
Chronic Bronchitis Product Profiles
Chronic Bronchitis Key Companies
Chronic Bronchitis Key Products
Dormant and Discontinued Products
Chronic Bronchitis Unmet Needs
Chronic Bronchitis Future Perspectives
Chronic Bronchitis Analyst Review
Appendix
Report Methodology

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Contact Us

Kanishk

kkumar@delveinsight.com

Athlete’s Foot Pipeline Insight

As per DelveInsight’s assessment, globally, Athlete’s Foot pipeline constitutes numerous key companies continuously working towards developing therapies for Athlete’s Foot treatment, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Athlete’s Foot Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers and acquisition, funding, designations, and other product-related details.

“Athlete’s Foot Pipeline Insight, 2026” report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Athlete’s Foot Market.

Recent Developments of Athlete’s Foot Market Report

In June 2025, Propedix, a dermatology-focused company dedicated to making skin health solutions more accessible, is set to launch its flagship over-the-counter product, Dryello. This treatment is designed specifically for an athlete’s foot (tinea pedis), with the dual goal of treating the condition and reducing the risk of recurrence. Dryello reflects the company’s focus on combining scientific rigor with practical, everyday dermatological care.
In June 2024, NYU Langone Health reported the first documented U.S. case of Trichophyton mentagrophytes type VII (TMVII), along with a rise in terbinafine-resistant T. indotineae infections. These findings highlight the increasing challenge of antifungal resistance in dermatophyte infections and emphasize the urgent need for new treatment strategies.

Athlete’s Foot Overview

Athlete’s Foot is a fungal infection that requires effective therapeutic interventions. The disease landscape continues to evolve with increasing awareness and healthcare spending globally.

Get a Free Sample PDF Report to know more about Athlete’s Foot Pipeline Therapeutic Assessment https://www.delveinsight.com/sample-request/athletes-foot-tinea-pedis-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Athlete’s Foot Route of Administration

Athlete’s Foot pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Topical

Athlete’s Foot Molecule Type

Athlete’s Foot Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Small molecule
Gene therapy

Athlete’s Foot Pipeline Therapeutics Assessment

Athlete’s Foot Assessment by Product Type
Athlete’s Foot By Stage and Product Type
Athlete’s Foot Assessment by Route of Administration
Athlete’s Foot By Stage and Route of Administration
Athlete’s Foot Assessment by Molecule Type
Athlete’s Foot by Stage and Molecule Type

DelveInsight’s Athlete’s Foot Report covers products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Further Athlete’s Foot product details are provided in the report. https://www.delveinsight.com/sample-request/athletes-foot-tinea-pedis-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Athlete’s Foot Pipeline Analysis:

The Athlete’s Foot pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Athlete’s Foot with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Athlete’s Foot Treatment.
Athlete’s Foot key players are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Athlete’s Foot Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Athlete’s Foot market.

Leading Organizations in the Athlete’s Foot Therapeutics Market Include:

Major companies advancing therapies for Myelofibrosis include Bausch Health , Dembiont , Blueberry Therapeutics , Novan , among others.

Athlete’s Foot Pipeline Market Drivers

Increase in R&D for the development of new and effective drugs for the treatment – Rising awareness of the disease, incremental healthcare spending across the world are some of the important factors that are fueling the Athlete’s Foot Market.

Athlete’s Foot Pipeline Market Barriers

However, challenges in R&D and other factors are creating obstacles in the Athlete’s Foot Market growth.

Scope of Athlete’s Foot Pipeline Drug Insight

Coverage: Global
Athlete’s Foot Therapeutic Assessment: Athlete’s Foot current marketed and Athlete’s Foot emerging therapies
Athlete’s Foot Market Dynamics: Athlete’s Foot market drivers and Athlete’s Foot market barriers

Request Sample PDF Report for Athlete’s Foot Pipeline Evaluation and clinical research https://www.delveinsight.com/sample-request/athletes-foot-tinea-pedis-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Table of Content

Report Introduction
Athlete’s Foot (Tinea Pedis)
Athlete’s Foot (Tinea Pedis) Current Treatment Patterns
Athlete’s Foot (Tinea Pedis) – DelveInsight’s Analytical Perspective
Therapeutic Assessment
Athlete’s Foot (Tinea Pedis) Late Stage Products (Phase-III)
Athlete’s Foot (Tinea Pedis) Mid Stage Products (Phase-II)
Early Stage Products (Phase-I)
Pre-clinical Products and Discovery Stage Products
Inactive Products
Dormant Products
Athlete’s Foot (Tinea Pedis) Discontinued Products
Athlete’s Foot (Tinea Pedis) Product Profiles
Athlete’s Foot (Tinea Pedis) Key Companies
Athlete’s Foot (Tinea Pedis) Key Products
Dormant and Discontinued Products
Athlete’s Foot (Tinea Pedis) Unmet Needs
Athlete’s Foot (Tinea Pedis) Future Perspectives
Athlete’s Foot (Tinea Pedis) Analyst Review
Appendix
Report Methodology

About DelveInsight

Contact Us

Kanishk

kkumar@delveinsight.com

Myelofibrosis Drug Development Pipeline: Comprehensive Market Analysis 2026

According to DelveInsight’s analysis, the worldwide Myelofibrosis development pipeline features over 35 major pharmaceutical companies actively engaged in advancing more than 40 therapeutic candidates for Myelofibrosis treatment. DelveInsight examines Clinical Trial data, therapeutic approaches, Mechanism of Action, Route of Administration, and developmental progress.

The Myelofibrosis Pipeline analysis encompasses thorough commercial and clinical evaluation of pipeline candidates spanning pre-clinical development through commercialized stages. The report includes comprehensive drug profiles, covering therapeutic mechanisms of action, clinical research, NDA regulatory approvals (where applicable), and development activities including technological innovations, partnerships, merger and acquisition activity, financial backing, regulatory designations, and additional product-specific information.

DelveInsight’s “Myelofibrosis Pipeline Insight, 2026” report delivers extensive insights into current clinical development landscapes and market expansion potential within the Myelofibrosis sector.

Key Highlights from the Myelofibrosis Pipeline Report:

Pharmaceutical organizations worldwide are actively pursuing innovative Myelofibrosis therapeutic solutions with notable achievements in recent years.
Organizations developing Myelofibrosis treatments include Lynk Pharmaceuticals, Samus Therapeutics, Taiga Biotechnologies, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Inc., Keros Therapeutics, Inc., Galecto Biotech AB, Actuate Therapeutics Inc., Karyopharm Therapeutics, AbbVie, Sierra Oncology, among additional companies advancing novel therapies.
Investigational Myelofibrosis treatments across various clinical trial phases include LNK01002, PU-H-71, TBX-2400, BMS-986158, TP-3654, KER-050, GB2064, 9-ING-41, Selinexor, Navitoclax, Momelotinib, among others, anticipated to substantially influence the Myelofibrosis therapeutic landscape.
In March 2026, China’s National Medical Products Administration (NMPA) has provided approval to Sino Biopharmaceutical Ltd.’s rovadicitinib, marketed under the brand name Anxu, for the first-line treatment of adult patients with intermediate- or high-risk primary myelofibrosis, including those with post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.
In September 2025, Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company specializing in innovative cancer treatments, disclosed that it has completed enrolling patients in the Phase 3 SENTRY trial. The study is evaluating selinexor combined with ruxolitinib in JAK inhibitor-naive patients with myelofibrosis.
In November 2024, MorphoSys reported favorable topline results from the Phase III MANIFEST-2 clinical trial assessing pelabresib for myelofibrosis. The trial evaluated pelabresib in combination with Jakafi (ruxolitinib) from Novartis and Incyte, compared to a placebo plus Jakafi, in JAK inhibitor-naive patients with myelofibrosis.
In October 2024, Ajax Therapeutics, Inc., a biopharmaceutical company focused on developing next-generation JAK inhibitors for myeloproliferative neoplasms (MPNs), has disclosed that the first patient has been dosed in its Phase 1 clinical trial of AJ111095, a novel Type II JAK2 inhibitor, for the treatment of myelofibrosis.

Understanding Myelofibrosis

Myelofibrosis is a rare type of bone marrow cancer that disrupts the body’s normal production of blood cells. This disease is part of a group of conditions known as myeloproliferative neoplasms. It results in extensive scarring (fibrosis) of the bone marrow, leading to severe anemia, weakness, fatigue, and often, an enlarged spleen (splenomegaly).

Access a Complimentary Sample PDF Report for additional information regarding Myelofibrosis Pipeline Therapeutic Evaluation: https://www.delveinsight.com/sample-request/myelofibrosis-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Investigational Myelofibrosis Therapeutics Across Clinical Development Stages Include:

JAKAFI/JAKAVI (ruxolitinib): Incyte/Novartis
INREBIC (fedratinib): Bristol Myers Squibb
XPOVIO (selinexor): Karyopharm Therapeutics
RYTELO (imetelstat): Geron Corporation
REBLOZYL (luspatercept/ACE-536): Bristol Myers Squibb
Navtemadlin (KRT-232): Kartos Therapeutics
Pelabresib (DAK539): Novartis
Bomedemstat (IMG-7289/MK-3543): Merck
TL-895: Telios Pharma
RVU120 (SEL-120): Ryvu Therapeutics
TP-3654 (nuvisertib): Syntara
DISC-0974: Disc Medicine
ELZONRIS (tagraxofusp/SL-401): Menarini Group

Administration Routes for Myelofibrosis Therapies

This Myelofibrosis pipeline analysis offers therapeutic evaluation of pipeline drugs organized by Route of Administration. Candidates have been classified under multiple administration routes, including:

Oral
Parenteral
Intravitreal
Subretinal
Topical
Molecule Type

Molecular Classifications for Myelofibrosis Products

Myelofibrosis Candidates have been organized under different Molecule types, including:

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type

Myelofibrosis Pipeline Therapeutic Evaluation

Myelofibrosis Evaluation by Product Type
Myelofibrosis By Development Stage and Product Type
Myelofibrosis Evaluation by Route of Administration
Myelofibrosis By Development Stage and Route of Administration
Myelofibrosis Evaluation by Molecule Type
Myelofibrosis by Development Stage and Molecule Type

DelveInsight’s Myelofibrosis Report encompasses approximately 40+ candidates across different clinical development phases including:

Advanced-stage candidates (Phase III)
Intermediate-stage candidates (Phase II)
Initial-stage candidates (Phase I)
Pre-clinical and Discovery phase programs
Discontinued & Inactive programs
Route of Administration

Additional Myelofibrosis product information is available in the report. Access the Myelofibrosis pipeline report to discover more regarding emerging Myelofibrosis therapeutic options https://www.delveinsight.com/sample-request/myelofibrosis-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Leading Organizations in the Myelofibrosis Therapeutics Sector Include:

Major companies advancing therapies for Myelofibrosis include Pharmaxis, Keros Therapeutics, Bristol-Myers Squibb, Ascentage Pharma Group Inc., Sumitomo Pharma Oncology, Galecto Biotech AB, Actuate Therapeutics Inc, Karyopharm Therapeutics Inc, AbbVie, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Taiga Biotechnologies, Inc., Rigel Pharmaceuticals, Celgene, Novartis Pharmaceuticals, Sierra Oncology, Inc., Incyte Corporation, Imago BioSciences, Inc., Samus Therapeutics, Inc., among others.

Myelofibrosis Pipeline Evaluation:

The Myelofibrosis pipeline report delivers insights into:

The report furnishes detailed information regarding organizations developing therapies for Myelofibrosis treatment along with cumulative therapies developed by individual companies.
It evaluates various therapeutic candidates organized into early-stage, mid-stage, and late-stage development for Myelofibrosis Treatment.
Myelofibrosis major companies engaged in targeted therapeutic development with corresponding active and inactive (dormant or discontinued) initiatives.
Myelofibrosis Drugs in development categorized by development stage, route of administration, target receptor, monotherapy or combination therapy, various mechanisms of action, and molecular classification.
Comprehensive analysis of partnerships (company-company alliances and company-academia partnerships), licensing agreements and funding details for future progression of the Myelofibrosis market.

The report utilizes data and information gathered from the researcher’s proprietary databases, organizational/academic websites, clinical trial databases, conferences, SEC documentation, investor briefings, and highlighted press releases from organizational/academic websites and industry-focused third-party resources.

Download Sample PDF Report for further information about Myelofibrosis drugs and therapeutic approaches https://www.delveinsight.com/sample-request/myelofibrosis-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Myelofibrosis Pipeline Market Growth Factors

Advancement in R&D for the development of new and effective drug for the treatment – Escalating Incidence in Elderly Population, development of biological therapies or immunotherapies represent key factors driving the Myelofibrosis Market.

Myelofibrosis Pipeline Market Challenges

Nevertheless, side effects associated with the drugs, elevated cost of therapy and additional factors present challenges to Myelofibrosis Market expansion.

Myelofibrosis Pipeline Drug Insight Scope

Coverage: Global
Key Myelofibrosis Companies: Lynk Pharmaceuticals, Samus Therapeutics, Taiga Biotechnologies, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Inc., Keros Therapeutics, Inc., Galecto Biotech AB, Actuate Therapeutics Inc., Karyopharm Therapeutics, AbbVie, Sierra Oncology, among others
Key Myelofibrosis Therapies: LNK01002, PU-H-71, TBX-2400, BMS-986158, TP-3654, KER-050, GB2064, 9-ING-41, Selinexor, Navitoclax, Momelotinib, among others
Myelofibrosis Therapeutic Evaluation: Myelofibrosis currently marketed and Myelofibrosis investigational therapies
Myelofibrosis Market Dynamics: Myelofibrosis market growth factors and Myelofibrosis market challenges

Request Sample PDF Report for Myelofibrosis Pipeline Evaluation and clinical research https://www.delveinsight.com/sample-request/myelofibrosis-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Table of Content

Myelofibrosis Report Introduction
Myelofibrosis Executive Summary
Myelofibrosis Overview
Myelofibrosis- Analytical Perspective In-depth Commercial Assessment
Myelofibrosis Pipeline Therapeutics
Myelofibrosis Late Stage Products (Phase II/III)
Myelofibrosis Mid Stage Products (Phase II)
Myelofibrosis Early Stage Products (Phase I)
Myelofibrosis Preclinical Stage Products
Myelofibrosis Therapeutics Assessment
Myelofibrosis Inactive Products
Company-University Collaborations (Licensing/Partnering) Analysis
Myelofibrosis Key Companies
Myelofibrosis Key Products
Myelofibrosis Unmet Needs
Myelofibrosis Market Drivers and Barriers
Myelofibrosis Future Perspectives and Conclusion
Myelofibrosis Analyst Views
Appendix
About DelveInsight

About DelveInsight

DelveInsight is a prominent Business Consultant and Market Research organization focused exclusively on life sciences. It supports Pharma companies by delivering comprehensive end-to-end solutions to enhance their performance. It also provides Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Contact Us

Kanishk

kkumar@delveinsight.com

Acromegaly Pipeline Insight 2026: Detailed Analysis of Novel Therapeutics and Clinical Development

DelveInsight’s “Acromegaly Pipeline Insight 2026” report delivers comprehensive insights about 10+ companies and 12+ pipeline drugs in the Acromegaly pipeline landscape. It encompasses the Acromegaly pipeline drug profiles, including clinical and nonclinical stage products. It also encompasses the Acromegaly pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Essential Highlights from the Acromegaly Pipeline Report

On March 17, 2026- Alexion Pharmaceuticals Inc. announced a phase 2 study is to assess the efficacy of 15-week treatment with ALXN2420 versus placebo for reducing insulin-like growth factor IGF-1 levels, when administered in combination with somatostatin analog (SSA) therapy to adult participants with acromegaly.
On March 02, 2026- Crinetics Pharmaceuticals Inc. launched a study designed to assess the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with non-pharmacologically treated acromegaly.
On February 03, 2026- Alexion Pharmaceuticals, Inc. initiated a phase 2 study is to assess the efficacy of 15-week treatment with ALXN2420 versus placebo for reducing insulin-like growth factor IGF-1 levels, when administered in combination with somatostatin analog (SSA) therapy to adult participants with acromegaly.
On January 30, 2026- Debiopharm International SA launched a phase 3 study is to evaluate the effect of Debio 4126 in the maintenance of the levels of insulin-like growth factor 1 (IGF-1) less than or equal to 1x upper limit of normal (ULN) in the double-blind period (Period 1) in comparison to placebo at week 36.
DelveInsight’s Acromegaly pipeline report illustrates a robust space with 10+ active players working to develop 12+ pipeline therapies for Acromegaly treatment.
The prominent Acromegaly Companies include Crinetics Pharmaceuticals Inc., Ipsen, Strongbridge Biopharma plc, Amryt Pharma Plc, Antisense Therapeutics Ltd, Percheron Therapeutics, Immunwork, among others.
Investigational Acromegaly Therapies include Paltusotine, CAM2029 (octreotide subcutaneous depot), GHR-LRX, Debio 4126, Octreotide capsules, Octreotide capsules, Lanreotide, Pasireotide LAR, among others.

Remain ahead with the most recent pipeline outlook for Acromegaly. Gain insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Acromegaly Treatment Drugs

The Acromegaly Pipeline Report delivers a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Acromegaly Pipeline Report also highlights the unmet needs with respect to Acromegaly.

Understanding Acromegaly

Acromegaly is a rare endocrine disorder caused by a benign tumor of pituitary gland that results in over-secretion of growth hormone (GH) that in turn causes abnormal increase in insulin-like growth factor-1 (IGF-1). Most pituitary adenomas are slow growing and benign. Symptoms include body odor, easy fatigue, headache, large feet, excessive height, swelling of the bony areas around a joint, widely spaced teeth, and sleep apnea. In adults, too much of this hormone causes bones, cartilage, body organs, and other tissues to increase in size.

Acromegaly Emerging Drugs Profile

Paltusotine: Crinetics Pharmaceuticals Inc.

Paltusotine is a first oral, once-daily, selectively targeted somatostatin receptor type 2 (SST2) agonist developed for the treatment of acromegaly. It was designed by Crinetics to provide a convenient once-daily option for people living with acromegaly. Paltusotine, an investigational drug for acromegaly, has received FDA acceptance of its New Drug Application (NDA). The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of September 25, 2025, for the NDA review. Currently it is in Registration stage of clinical trial evaluation to treat Acromegaly. The drug maintained the IGF-1 levels in acromegaly patients in both Phase II and in recent Phase III studies.

Atesidorsen: Percheron Therapeutics

Atesidorsen (formerly ATL1103) is a second-generation antisense oligonucleotide developed by Percheron Therapeutics for the treatment of acromegaly, a hormonal disorder characterized by excess growth hormone and elevated IGF-1 levels. The therapy works by inhibiting the human growth hormone receptor (GHr), thereby reducing IGF-1 production. Atesidorsen showed promising results in a Phase II clinical trial, demonstrating its potential to normalize IGF-1 levels in patients. However, in April 2025, Percheron Therapeutics announced the discontinuation of atesidorsen’s development, citing limited commercial viability under current development pathways. Currently the drug is in Phase II stage of its development for the treatment of Acromegaly.

TE 8214: Immunwork

TE8214 is a next-generation somatostatin receptor agonist designed by Immunwork (TE Pharma Holding) for the treatment of acromegaly and neuroendocrine tumors. Its highly water-soluble, fatty-acid-conjugated peptide formulation enables subcutaneous administration with a fine 30-gauge needle, virtually eliminating injection-site pain and nodules seen with current therapies. In the Phase I single-ascending dose trial (completed late 2024), TE8214 was exceptionally well tolerated: in the highest dose groups, about 83% of participants achieved >20% reduction in IGF1, with minimal gastrointestinal side-effects. Based on this strong safety and pharmacodynamic profile, Immunwork plans to initiate Phase II trials in Taiwan in Q3 2025 and is actively seeking strategic partnerships to support global development. Currently the drug is in Phase I stage of its development for the treatment of Acromegaly.

Discover groundbreaking therapies and clinical trials in the Acromegaly Pipeline. Access DelveInsight’s detailed report now! @ New Acromegaly Drugs

The Acromegaly Pipeline Report Delivers Insights into

The report furnishes detailed insights about companies that are developing therapies for the treatment of Acromegaly with aggregate therapies developed by each company for the same.
It evaluates the various therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acromegaly Treatment.
Acromegaly Companies are engaged in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Acromegaly Drugs under development categorized by the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Comprehensive analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acromegaly market.

Acromegaly Companies

Crinetics Pharmaceuticals Inc., Ipsen, Strongbridge Biopharma plc, Amryt Pharma Plc, Antisense Therapeutics Ltd, Percheron Therapeutics, Immunwork, among others.

Acromegaly pipeline report delivers the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Acromegaly Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Reveal the future of Acromegaly Treatment. Discover new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Acromegaly Market Drivers and Barriers

Scope of the Acromegaly Pipeline Report

Coverage- Global
Acromegaly Companies- Crinetics Pharmaceuticals Inc., Ipsen, Strongbridge Biopharma plc, Amryt Pharma Plc, Antisense Therapeutics Ltd, Percheron Therapeutics, Immunwork, among others.
Acromegaly Therapies- Paltusotine, CAM2029 (octreotide subcutaneous depot), GHR-LRX, Debio 4126, Octreotide capsules, Octreotide capsules, Lanreotide, Pasireotide LAR, among others.
Acromegaly Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Acromegaly Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Obtain the latest on Acromegaly Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Acromegaly Companies, Key Products and Unmet Needs

Table of Content

Introduction
Executive Summary
Acromegaly: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
Comparative Analysis
Paltusotine: Crinetics Pharmaceuticals Inc.
Product Description
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Atesidorsen: Percheron Therapeutics
Early Stage Products (Phase I)
Comparative Analysis
TE 8214: Immunwork
Inactive Products
Acromegaly Key Companies
Acromegaly Key Products
Acromegaly- Unmet Needs
Acromegaly- Market Drivers and Barriers
Acromegaly- Future Perspectives and Conclusion
Acromegaly Analyst Views
Acromegaly Key Companies
Appendix

About Us

Contact Us

Kanishk

kkumar@delveinsight.com

Asthma Pipeline Insight 2026: Comprehensive Analysis of Emerging Therapies and Key Developments

DelveInsight’s “Asthma Pipeline Insight 2026” report delivers comprehensive insights about 80+ companies and 90+ pipeline drugs in the Asthma pipeline landscape. It encompasses the Asthma pipeline drug profiles, including clinical and nonclinical stage products. It also encompasses the Asthma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Essential Highlights from the Asthma Pipeline Report

On April 17, 2026- Eli Lilly and Company announced a phase 2 study is to evaluate the safety and efficacy of brenipatide at various dose levels compared with placebo in participants with moderate-to-severe asthma. Study participation will last approximately 65 weeks, including screening, treatment, and follow-up periods.
On April 14, 2026- AstraZeneca launched a Phase III study to assess the efficacy and safety of BDA MDI compared with AS MDI in minimizing the risk of a severe asthma exacerbation in symptomatic Chinese adults with asthma.
On April 13, 2026- Arrowhead Pharmaceuticals initiated a phase 2a study is to assess the impact of inhaled ARO-RAGE on the late asthmatic response (LAR) following an inhaled allergen challenge in participants with mild atopic asthma.
On April 09, 2026- Sanofi launched a phase 2 study to assess the long-term safety and efficacy of lunsekimig in adult participants with asthma who have previously completed the parent studies. After completion of the parent study, eligible participants will be offered the opportunity to participate in the long-term extension (LTE) study with lunsekimig.
DelveInsight’s Asthma pipeline report illustrates a robust space with 80+ active players working to develop 90+ pipeline therapies for Asthma treatment.
The prominent Asthma Companies include GlaxoSmithKline, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Oneness Biotech Co., Ltd., Arrowhead Pharmaceuticals, Areteia Therapeutics, Jiangsu HengRui Medicine, SinoMab BioScience Ltd, Incyte Corporation, CSPC ZhongQi Pharmaceutical, Advagene Biopharma Co. Ltd., Beijing Kanova Biopharmaceutical, Inmunotek, Roche, Sanofi, ARS Pharmaceuticals, among others.
Investigational Asthma Therapies include HSK31858, Dexpramipexole Dihydrochloride, Benralizumab, Dupilumab, Rocatinlimab, Mepolizumab, among others.

Remain informed about the cutting-edge advancements in Asthma treatments @ Asthma Clinical Trials Assessment

The Asthma Pipeline Report delivers disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Asthma Pipeline Report also highlights the unmet needs with respect to Asthma.

Understanding Asthma

Asthma is a chronic disease of the air passages characterized by inflammation and narrowing of the airways. Symptoms of asthma include shortness of breath, cough, and wheezing. It commonly presents in childhood and is usually associated with conditions such as eczema and hay fever. Asthma comprises a range of diseases and has a variety of heterogeneous phenotypes. The recognized factors that are associated with asthma are a genetic predisposition, specifically a personal or family history of atopy (propensity to allergy, usually seen as eczema, hay fever, and asthma).

Asthma Emerging Drugs Profile

GSK3511294: GlaxoSmithKline

GSK’294 is an anti-IL-5 monoclonal antibody currently in development for the treatment of severe eosinophilic asthma. It is a distinct, new biologic entity and has been engineered for high affinity and long-acting suppression of IL-5 function. IL-5 is the major cytokine responsible for the proliferation, activation and survival of eosinophils, making it a proven treatment target for severe asthma patients with higher levels of eosinophils. In patients with severe eosinophilic asthma, targeted anti-IL-5 therapies are a well-established and effective treatment approach. GSK3511294 is currently being evaluated in Phase III stage of Clinical trial development for the treatment of Asthma.

TQC2731: Chia Tai Tianqing Pharmaceutical Group

TQC2731, belongs to the class of Antiasthmatic. These anti-inflammatory drugs are the most effective and commonly used long-term control medications for asthma. They reduce swelling and tightening in the airways. An Antiasthmatic and antiallergic agent also prevents mast cell release of histamine and formation of other mediators (leukotrienes) of anaphylaxis by inhibiting degranulation after contact with antigens. These helps prevent symptoms of asthma, allergic rhinitis, mastocytosis, and exercise-induced bronchospasm. TQC2731 is currently being evaluated in Phase II stage of Clinical trial development for the treatment of Asthma.

AZD4604: AstraZeneca

AZD4604 is a potent and selective inhibitor of Janus kinase family member, JAK1, intended for inhaled add-on treatment of moderate to severe asthma, uncontrolled on standard of care. Due to the broad anti-inflammatory properties of JAK1 inhibition, AZD4604 is predicted to provide benefit to steroid sensitive and insensitive asthma endotypes, thereby offering a differentiation opportunity from existing biologics. It is currently being evaluated in Phase II stage of Clinical trial development for the treatment of Asthma.

FB704A: Oneness Biotech Co., Ltd.

FB704A is a fully human monoclonal antibody that inhibits IL-6/IL-6R signaling pathway by neutralizing IL-6. FB704A (anti-IL-6 Ab) can reduce bronchial hyperresponsiveness as well as the Th1, Th2, and Th17 inflammatory responses of the respiratory tract, inhibit IL-6 classic- and trans-signaling pathways, and therefore have a chance of improving the symptoms of severe asthma (with high neutrophils) and severe mixed-granulocytic asthma. It is currently being evaluated in Phase II stage of Clinical trial development for the treatment of Asthma.

ARO-RAGE: Arrowhead Pharmaceuticals

ARO-RAGE is designed to reduce production of the Receptor for Advanced Glycation End products (RAGE) as a potential treatment for various muco-obstructive and inflammatory pulmonary diseases. It is currently being evaluated in Phase I stage of Clinical trial development for the treatment of Asthma.

Discover more about Asthma Drugs opportunities in our groundbreaking Asthma Research and development projects @ Asthma Unmet Needs

The Asthma Pipeline report delivers insights into

The report furnishes detailed insights about companies that are developing therapies for the treatment of Asthma with aggregate therapies developed by each company for the same.
It evaluates the various therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Asthma Treatment.
Asthma Companies are engaged in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Asthma Drugs under development categorized by the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Comprehensive analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Asthma market.

Asthma Companies

GlaxoSmithKline, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Oneness Biotech Co., Ltd., Arrowhead Pharmaceuticals, Areteia Therapeutics, Jiangsu HengRui Medicine, SinoMab BioScience Ltd, Incyte Corporation, CSPC ZhongQi Pharmaceutical, Advagene Biopharma Co. Ltd., Beijing Kanova Biopharmaceutical, Inmunotek, Roche, Sanofi, ARS Pharmaceuticals, among others.

Asthma pipeline report delivers the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Asthma Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Explore the latest advancements in Asthma treatment by visiting our website @ Asthma Market Drivers and Barriers, and Future Perspectives

Scope of the Asthma Pipeline Report

Coverage- Global
Asthma Companies- GlaxoSmithKline, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Oneness Biotech Co., Ltd., Arrowhead Pharmaceuticals, Areteia Therapeutics, Jiangsu HengRui Medicine, SinoMab BioScience Ltd, Incyte Corporation, CSPC ZhongQi Pharmaceutical, Advagene Biopharma Co. Ltd., Beijing Kanova Biopharmaceutical, Inmunotek, Roche, Sanofi, ARS Pharmaceuticals, among others.
Asthma Therapies- HSK31858, Dexpramipexole Dihydrochloride, Benralizumab, Dupilumab, Rocatinlimab, Mepolizumab, among others.
Asthma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Asthma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Access the full details of Asthma Pipeline on our website @ Asthma Emerging Drugs and Companies

Table of Content

Introduction
Executive Summary
Asthma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Asthma- DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
GSK3511294: GlaxoSmithKline
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
TQC2731: Chia Tai Tianqing Pharmaceutical Group
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
ARO-RAGE: Arrowhead Pharmaceuticals
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Asthma Key Companies
Asthma Key Products
Asthma- Unmet Needs
Asthma- Market Drivers and Barriers
Asthma- Future Perspectives and Conclusion
Asthma Analyst Views
Asthma Key Companies
Appendix

About Us

Contact Us

Kanishk

kkumar@delveinsight.com

Essential Highlights from the Lower-Limb Spasticity Market Report

Lower-Limb Spasticity Epidemiology Classification in the 7MM

Lower-Limb Spasticity Drugs Market

Lower-Limb Spasticity Treatment Market Landscape

Lower-Limb Spasticity Market Outlook

Lower-Limb Spasticity Drugs Uptake

Leading Lower-Limb Spasticity Companies

Parameters of the Lower-Limb Spasticity Market Report

Table of Content

About Us

Contact Information

Essential Highlights from the Chronic and Acute Pain Market Report

Chronic and Acute Pain Epidemiology Classification in the 7MM

Chronic and Acute Pain Drugs Market

Chronic and Acute Pain Treatment Market Landscape

Chronic and Acute Pain Market Outlook

Chronic and Acute Pain Drugs Uptake

Leading Chronic and Acute Pain Companies

Parameters of the Chronic and Acute Pain Market Report

Table of Contents

About Us

Contact Information

Key Takeaways from the JAK Inhibitors Market Research Report

JAK Inhibitors Epidemiology Segmentation in the 7MM

JAK Inhibitors Emerging Drugs

JAK Inhibitors Drugs Market Insights

JAK Inhibitors Market Outlook

JAK Inhibitors Companies

JAK Inhibitors Treatment Landscape

Scope of the JAK Inhibitors Market Report

Table of Content

About Us

Contact Information

Recent Developments of Physiotherapy Equipment Clinical Trials

Key Takeaways from the Physiotherapy Equipment Market Report

Physiotherapy Equipment Market Segmentation

Physiotherapy Equipment Market

Physiotherapy Equipment Market Landscape

Physiotherapy Equipment Market Outlook

Physiotherapy Equipment Market Dynamics

Major Physiotherapy Equipment Companies

Scope of the Physiotherapy Equipment Market Report

Table of Content

About Us

Contact Information

Some of the key facts of the DNA Microarray Market Report:

DNA Microarray Overview

DNA Microarray Market Insights

DNA Microarray Market Segmentation:

DNA Microarray Market Uptake and Technology Development Activities

DNA Microarray Technology and Key Companies

DNA Microarray Market Drivers

DNA Microarray Market Barriers

Scope of the DNA Microarray Market Report

About DelveInsight

Contact Information

Some of the key takeaways from the Chronic Bronchitis Pipeline Report:

Chronic Bronchitis Overview

Chronic Bronchitis Route of Administration

Chronic Bronchitis Molecule Type

Chronic Bronchitis Pipeline Therapeutics Assessment

Chronic Bronchitis Pipeline Analysis:

Chronic Bronchitis Pipeline Market Drivers

Chronic Bronchitis Pipeline Market Barriers

Scope of Chronic Bronchitis Pipeline Drug Insight

Table of Contents

About DelveInsight

Contact Us

Recent Developments of Athlete’s Foot Market Report

Athlete’s Foot Overview

Athlete’s Foot Route of Administration

Athlete’s Foot Molecule Type

Athlete’s Foot Pipeline Therapeutics Assessment

Athlete’s Foot Pipeline Analysis:

Leading Organizations in the Athlete’s Foot Therapeutics Market Include:

Athlete’s Foot Pipeline Market Drivers

Athlete’s Foot Pipeline Market Barriers

Scope of Athlete’s Foot Pipeline Drug Insight

Table of Content

About DelveInsight